A talar osteochondral defect (OCD) is a combined lesion of the subchondral bone and its overlying cartilage.^[@bibr70-2325967119876238]^ Patients suffering from these defects typically experience persistent or intermittent deep ankle pain during or after activity.^[@bibr20-2325967119876238]^

The treatment of talar OCDs is usually initiated with a nonoperative protocol. However, surgical treatment is often required, as most talar OCDs remain symptomatic after nonoperative treatment.^[@bibr95-2325967119876238]^ The literature reports a wide variety of surgical treatment strategies, with surgical options ranging from regenerative to replacement therapies.^[@bibr33-2325967119876238],[@bibr73-2325967119876238],[@bibr79-2325967119876238],[@bibr80-2325967119876238],[@bibr83-2325967119876238]^ In general, all of the different surgical treatment strategies for talar OCDs have shown good results, and there is no clear evidence regarding a superior treatment strategy for either primary or secondary defects.^[@bibr10-2325967119876238],[@bibr45-2325967119876238]^

When studying the evidence of outcomes in athletes, it is clear that even less is known in this specific patient group.^[@bibr81-2325967119876238]^ Athletes have different needs for treatment compared with the general population. While a number of studies have focused on sports-related outcomes after the surgical treatment of talar OCDs,^[@bibr14-2325967119876238],[@bibr34-2325967119876238],[@bibr69-2325967119876238],[@bibr91-2325967119876238],[@bibr93-2325967119876238]^ there is, to our knowledge, no available systematic review including all surgical treatment options for talar OCDs, with associated sports-specific outcomes. With the high incidence of talar OCDs seen in athletes, there is a need for an overview and comparison of sports-related outcomes of the available surgical treatment strategies.

The aim of the present review was therefore to summarize the available evidence regarding sports outcomes for different surgical treatment options by calculating the rate of return to sports (RTS), the mean RTS time, and data on other sports-related outcomes of talar OCD surgery.

Methods {#section1-2325967119876238}
=======

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) statement was used as a guideline for the study. The systematic review was prospectively registered at the PROSPERO database with reference number CRD42018080718.^[@bibr7-2325967119876238]^

Search Strategy {#section2-2325967119876238}
---------------

The electronic databases of PubMed (MEDLINE), Embase, Cochrane Database of Systematic Reviews, DARE, and CENTRAL were screened for potentially suitable studies from January 1996 to November 2018. The full search strategy for all electronic databases is outlined in [Appendix Table A1](#table11-2325967119876238){ref-type="table"}. Because not all titles or abstracts in these databases clearly describe whether they report any results regarding sports outcomes, narrower terms such as "sports" or "activity" were not used in our search strategy, as this would potentially exclude eligible studies.

Eligibility Criteria and Study Selection {#section3-2325967119876238}
----------------------------------------

All studies reporting sports-related outcomes after the surgical treatment of talar OCDs were included. The exclusion criteria are reported in [Table 1](#table1-2325967119876238){ref-type="table"}. When necessary, authors were contacted to provide information on any patient overlap or to provide separate data for their patients when results were given for a combination of diagnoses or a combination of treatment groups. When no reply was reported, contact was sought by 2 reminder emails. If no response was recorded, the specific article was excluded. An independent evaluation of the articles and a subsequent discussion were performed by 2 reviewers (J.A.H.S. and J.D.) after title and abstract screening and full-text reading. In case of a disagreement after a discussion at any point in time in the evaluation process, the opinion from a third investigator (G.M.M.J.K.) was consulted and decisive. Studies were not blinded for author, affiliation, or source. Only studies published in English, German, French, Dutch, or Spanish were included. No limitations were put on publication status. No restrictions were set on publication date or the patient age.

###### 

Exclusion Criteria

![](10.1177_2325967119876238-table1)

  ---------------------------------------------------------------------------
  No sports outcomes reported
  Combination of diagnoses
  Patient overlap
  Written in language other than English, German, French, Dutch, or Spanish
  Fewer than 5 patients
  Combination of treatment groups, although no separate data per group
  No surgical treatment
  ---------------------------------------------------------------------------

Critical Appraisal {#section4-2325967119876238}
------------------

Methodological quality was assessed for all included studies using the MINORS (Methodological Index for Non-Randomized Studies) criteria ([Appendix Table A2](#table12-2325967119876238){ref-type="table"}).^[@bibr82-2325967119876238]^ Each study was graded on methodological quality by 2 independent reviewers (J.A.H.S. and J.D.), after which any conflicting outcomes were resolved by a discussion. In case of persisting conflict, the senior author (G.M.M.J.K.) was consulted, whose opinion was decisive.

Data Extraction {#section5-2325967119876238}
---------------

To retrieve data on study characteristics, a standardized form was used. Acquired data on patient characteristics included age, sex, number of patients and ankles, stage of the defect, whether the defect was primary or secondary, preinjury activity level, mean follow-up duration, and the reported OCD classification system. Preoperative and postoperative clinical outcomes regarding sports activity were extracted and included mean scores, number of patients participating in sports activity, activity level, and RTS time. Described treatment techniques were examined per study, after which they were divided into corresponding treatment groups. In case of the presence of other sports-related clinical outcomes, these were additionally extracted from the studies and pooled as well as subsequently analyzed where possible.

Statistical and Data Analyses {#section6-2325967119876238}
-----------------------------

To analyze the identified studies with regard to RTS and the mean time to RTS, the definition of these measures need to be clear. In this study, we distinguished 2 types of RTS: return with level specified, where the patients had to perform in the same sport at the same level as preinjury; and return without specified level, where the patients could participate in any sport at any level, regardless of their performance before their injury.^[@bibr2-2325967119876238]^ The mean time to RTS was defined as the mean time at which patients could resume their sports activity, regardless of which sport and at what level. When studies are found to be highly different in methodological nature, a formal meta-analysis cannot be performed. Thus, a simplified pooling method was used to combine data from different studies using corresponding methodologies to provide results within 1 treatment group. Moreover, 95% confidence intervals (binomial proportion) for the RTS rates of each study and the pooled studies were calculated with the Wilson score interval. Additionally, the mean time to RTS was calculated and pooled whenever possible. A comparison of different sports outcomes by means of formal statistical tests with accompanying *P* values was not deemed methodologically suitable for the present review, as the specific clinical indications for specific surgical therapies were highly different from one another; that is, the prognosis of a surgical outcome for talar OCDs correlates substantially with prognostic factors such as size, primary or nonprimary nature, patient age, and location.^[¶](#fn1-2325967119876238){ref-type="fn"}^

Results {#section7-2325967119876238}
=======

Search Results {#section8-2325967119876238}
--------------

The literature search using the selected databases provided 1776 articles. After removal of duplicates and application of the eligibility criteria to the titles and abstracts, 536 articles were found to be potentially suitable and were included for a full-text review. Consequently, the full-text articles were screened, and the inclusion and exclusion criteria were applied. The authors of 15 studies were contacted through email for additional data according to our inclusion criteria. Subsequently, 2 studies were able to be included, and 13 had to be excluded attributable to this author contact process.

In total, 475 studies had to be excluded. An overview of the excluded studies by exclusion criteria is shown in [Table 2](#table2-2325967119876238){ref-type="table"}. This left 61 suitable studies available for review. The literature selection algorithm according to the PRISMA guidelines is shown in [Figure 1](#fig1-2325967119876238){ref-type="fig"}.^[@bibr49-2325967119876238]^

###### 

Excluded Studies by Exclusion Criteria

![](10.1177_2325967119876238-table2)

  Exclusion Criteria                                                          No. of Studies
  --------------------------------------------------------------------------- ----------------
  No sports outcomes reported                                                 416
  Combination of diagnoses                                                    22
  Patient overlap                                                             18
  Written in language other than English, German, French, Dutch, or Spanish   10
  Fewer than 5 patients                                                       5
  Combination of treatment groups, although no separate data per group        3
  No surgical treatment                                                       1
  Total                                                                       475

![Literature selection algorithms using PRISMA guidelines.](10.1177_2325967119876238-fig1){#fig1-2325967119876238}

Characteristics of the Included Studies {#section9-2325967119876238}
---------------------------------------

A total of 2347 talar OCDs were included in the 61 studies. The mean patient age was 32 years (range, 11-72 years), and the percentage of female and male patients was 37% and 63%, respectively. The most frequently used clinical scoring system and osteochondral damage classification system were the American Orthopaedic Foot & Ankle Society (AOFAS) score and the Berndt and Harty^[@bibr5-2325967119876238]^ classification system, respectively.^[@bibr40-2325967119876238]^ The mean follow-up time ranged from 11 to 144 months.

Methodological Quality {#section10-2325967119876238}
----------------------

A full consensus on methodological quality was reached after independent grading and a subsequent discussion by the 2 reviewers. Of the 61 studies, 52 were noncomparative prospective or retrospective studies and had an average MINORS score of 8.0 (range, 3-13) out of a possible 16 points. The remaining 9 were comparative studies and had an average MINORS score of 18.8 (range, 12-22) out of a possible 24 points. A full overview of the scores by study is shown in [Appendix Table A3](#table13-2325967119876238){ref-type="table"}.

Treatment Strategies {#section11-2325967119876238}
--------------------

Seven different treatment groups were formed out of the different treatment strategies ([Table 3](#table3-2325967119876238){ref-type="table"}). As there were several studies that reported outcomes for multiple treatment options (ie, comparative study), the total number of treatment strategies is higher than the total number of included studies. A simplified pooling method was used for studies with the same methodology (eg, all retrospective case series together) that reported on the same outcomes after performing the same treatment technique.

###### 

Included Treatment Groups (61 Included Studies)*^a^*

![](10.1177_2325967119876238-table3)

                                                                      No. of Surgical Treatment Options
  ------------------------------------------------------------------- -----------------------------------
  BMS                                                                 25
   BMS without additional therapies                                   22
   BMS with platelet-rich plasma or mesenchymal stem cell injection   2
   BMS with pulsed electromagnetic field therapy                      1
  Internal fixation                                                   2
   Drilling + fixation                                                2
  Retrograde drilling                                                 1
   Retrograde drilling with cancellous bone grafting                  1
  Osteo(chondral) transplantation                                     22
   Autograft                                                          13
   Mosaicplasty                                                       4
   Synthetic graft                                                    2
   Allograft                                                          1
   Autograft and cancellous bone allograft                            1
   Osteoperiosteal cylinder graft                                     1
  Cartilage implantation                                              9
   Autologous chondrocyte implantation                                6
   Matrix-induced autologous chondrocyte implantation                 2
   Particulated juvenile cartilage implantation                       1
  Chondrogenesis-inducing techniques                                  10
   Scaffold-based therapies                                           6
   Autologous matrix-induced chondrogenesis                           4
  Metal implantation                                                  2
   Metal resurfacing implant (HemiCAP)                                2
  Total                                                               71

*^a^*As there were several studies that reported outcomes for multiple treatment options (ie, comparative study), the total number of treatment strategies is higher than the total number of included studies. BMS, bone marrow stimulation.

Reported Outcomes {#section12-2325967119876238}
-----------------

The included studies reported on sports-related outcomes by different means. [Figure 2](#fig2-2325967119876238){ref-type="fig"} shows an overview of the number of studies reporting on the main chosen outcome measures (RTS with and without specified level and mean time to RTS) by treatment strategy. An overview of the reported outcomes by study is shown in [Appendix Table A4](#table14-2325967119876238){ref-type="table"}.

![Overview of reported outcomes by treatment strategy. BMS, bone marrow stimulation; RTS, return to sports.](10.1177_2325967119876238-fig2){#fig2-2325967119876238}

### Bone Marrow Stimulation (Debridement and/or Drilling) {#section13-2325967119876238}

Bone marrow stimulation (BMS) aims at forming local new blood vessels and stimulating fibrocartilaginous tissue.^[@bibr70-2325967119876238]^ Additionally, platelet-rich plasma or mesenchymal stem cell injections can be used to improve cartilage regeneration.^[@bibr26-2325967119876238],[@bibr38-2325967119876238]^ Another possibility is the use of pulsed electromagnetic field therapy.^[@bibr69-2325967119876238]^ There were 23 studies describing the sports-related results of BMS in a total of 1243 patients.^[\#](#fn2-2325967119876238){ref-type="fn"}^ An overview of the study characteristics, patient characteristics, and outcomes within this group is shown in [Table 4](#table4-2325967119876238){ref-type="table"}.

###### 

Overview of Study Characteristics, Patient Characteristics, and Outcomes for Bone Marrow Stimulation*^a^*

![](10.1177_2325967119876238-table4)

  -------------------------------------------------------------- -----------------
  No. of studies                                                 23*^b^*
  No. of patients                                                1243
  Study type, n                                                  
   Retrospective case series                                     12
   Randomized controlled trials                                  3
   Retrospective comparative studies                             3
   Prospective comparative studies                               2
   Prospective case series                                       2
   Retrospective cohort studies                                  1
  Follow-up duration,*^c^* mo                                    16-144
  Defects (n = 1185), n (%)                                      
   Primary                                                       1143 (96)
   Secondary                                                     42 (4)
  Berndt and Harty classification (n = 361), n (%)               
   Stage I                                                       47 (13)
   Stage II                                                      155 (43)
   Stage III                                                     119 (33)
   Stage IV                                                      40 (11)
  RTS rate (n = 389),*^c^* mean (95% CI), %                      76-100 (67-100)
  RTS rate to preinjury level (n = 195),*^c^* mean (95% CI), %   18-100 (6-100)
  Time to RTS (n = 215),*^c^* wk                                 15-26
  -------------------------------------------------------------- -----------------

*^a^*RTS, return to sports.

*^b^*References [@bibr6-2325967119876238], [@bibr15-2325967119876238], [@bibr17-2325967119876238], [@bibr18-2325967119876238], [@bibr20-2325967119876238], [@bibr26-2325967119876238], [@bibr29-2325967119876238], [@bibr35-2325967119876238], [@bibr38-2325967119876238], [@bibr41-2325967119876238], [@bibr43-2325967119876238], [@bibr47-2325967119876238], [@bibr54-2325967119876238], [@bibr58-2325967119876238] [@bibr59-2325967119876238]--[@bibr60-2325967119876238], [@bibr69-2325967119876238], [@bibr75-2325967119876238], [@bibr76-2325967119876238], [@bibr85-2325967119876238], [@bibr88-2325967119876238], [@bibr92-2325967119876238], [@bibr94-2325967119876238].

*^c^*Range of means of original data.

A simplified pooling method was used for 10 of the 12 retrospective case series, with a total of 339 patients.[\*\*](#fn3-2325967119876238){ref-type="fn"} When pooled, it was calculated that 88% (95% CI, 84%-91%) of the patients were able to return to sports regardless of the level of sports activity ([Table 5](#table5-2325967119876238){ref-type="table"}). There were 6 studies that specified the level of sports activity postoperatively in a total of 120 patients.^[@bibr18-2325967119876238],[@bibr20-2325967119876238],[@bibr43-2325967119876238],[@bibr59-2325967119876238],[@bibr60-2325967119876238],[@bibr75-2325967119876238]^ Of these patients, 79% (95% CI, 70%-85%) were able to participate in sports at their preinjury level, while 18% (95% CI, 12%-26%) had some limitations and 3% (95% CI, 1%-7%) were unable to return ([Table 6](#table6-2325967119876238){ref-type="table"}).

###### 

Mean Pooled Rates of Return to Any Level of Sports*^a^*

![](10.1177_2325967119876238-table5)

  Surgical Treatment                          Study Type                     No. of Patients   Rate of RTS at Any Level, %
  ------------------------------------------- ------------------------------ ----------------- -----------------------------
  Bone marrow stimulation                     10 retrospective case series   339               88 (95% CI, 84-91)
  Internal fixation                           2 retrospective case series    47                97 (95% CI, 85-99)
  Osteochondral autograft transplant system   5 retrospective case series    195               90 (95% CI, 86-94)
  Autologous chondrocyte implantation         3 prospective case series      39                87 (95% CI, 73-94)

*^a^*RTS, return to sports.

###### 

Mean Pooled Rates of Return to Preinjury Level of Sports*^a^*

![](10.1177_2325967119876238-table6)

  Surgical Treatment                          Study Type                    No. of Patients   Rate of RTS at Preinjury Level, %
  ------------------------------------------- ----------------------------- ----------------- -----------------------------------
  Bone marrow stimulation                     6 retrospective case series   120               79 (95% CI, 70-85)
  Osteochondral autograft transplant system   4 prospective case series     67                72 (95% CI, 60-83)
  Autologous chondrocyte implantation         3 prospective case series     39                69 (95% CI, 54-81)

*^a^*RTS, return to sports.

A variety of outcome measures were reported within this group, the most commonly used being the Foot and Ankle Outcome Score (FAOS) sports score, reported by 5 studies.^[@bibr35-2325967119876238],[@bibr41-2325967119876238],[@bibr47-2325967119876238],[@bibr54-2325967119876238],[@bibr92-2325967119876238]^ Mean follow-up times ranged from 31 to 118 months. Mean preoperative scores ranged from 35.5 to 67.6, and mean postoperative scores ranged from 48.9 to 82.2. No correlations were observed between the length of the follow-up period and the increase in the FAOS sports score. The Tegner score was also reported by 4 studies within this group.^[@bibr6-2325967119876238],[@bibr38-2325967119876238],[@bibr85-2325967119876238],[@bibr94-2325967119876238]^ Mean follow-up times ranged from 22 to 67 months. Mean preoperative scores ranged from 1.8 to 6.2, and mean postoperative scores ranged from 3.6 to 5.9. No correlations were observed between the length of the follow-up period and the increase in the Tegner score. Other reported scores within this group were the Ankle Activity Score (AAS), reported by 2 studies,^[@bibr69-2325967119876238],[@bibr92-2325967119876238]^ the Karlsson score, reported by 1 study,^[@bibr6-2325967119876238]^ and the Foot and Ankle Ability Measure (FAAM) sports subscale, reported by 1 study.^[@bibr26-2325967119876238]^ Because of low reporting, these scores were not further analyzed.

### Internal Fixation {#section14-2325967119876238}

This treatment technique can be considered when large, loose osteochondral fragments are apparent in the joint, while the subchondral bone is still vital. Two studies with a total of 47 patients were identified.^[@bibr44-2325967119876238],[@bibr77-2325967119876238]^ The mean follow-up duration ranged from 46 to 84 months. There were 13% of OCDs classified as stage I, 68% as stage II, 17% as stage III, and 2% as stage IV. Both studies were retrospective case series, reporting on RTS; therefore, the results for this treatment group were pooled. Of the 47 patients, 97% (95% CI, 85%-99%) were able to return to sports postoperatively, regardless of preinjury and postinjury sports levels, as no results regarding the specific level of sports activity or mean time to RTS were reported within this treatment group ([Table 5](#table5-2325967119876238){ref-type="table"}).

### Retrograde Drilling {#section15-2325967119876238}

The aim of this technique is to revascularize the subchondral bone and subsequently to achieve the formation of new bone.^[@bibr70-2325967119876238]^ One study (a retrospective case series) was included in this treatment group,^[@bibr72-2325967119876238]^ including 15 patients all with primary defects and a mean follow-up of 12 months.

This study solely reported results on the FAOS sports score, not on RTS rates or times. No pooling could be performed.

### Osteo(chondral) Transplantation {#section16-2325967119876238}

Talar OCDs can be treated by several osteo(chondral) transplantation techniques: osteochondral autograft transplant system, mosaicplasty, autogenous bone graft transplantation, osteochondral allograft transplantation, and osteoperiosteal cylinder graft implantation.

There were 21 studies (643 patients) describing sports-related results.^[††](#fn4-2325967119876238){ref-type="fn"}^ An overview of the study characteristics, patient characteristics, and outcomes within this group is shown in [Table 7](#table7-2325967119876238){ref-type="table"}.

###### 

Overview of Study Characteristics, Patient Characteristics, and Outcomes for Osteo(chondral) Transplantation*^a^*

![](10.1177_2325967119876238-table7)

  -------------------------------------------------------------- ----------------
  No. of studies                                                 21*^b^*
  No. of patients                                                643
  Study type, n                                                  
   Retrospective case series                                     11
   Prospective case series                                       6
   Randomized controlled trials                                  2
   Prospective comparative studies                               1
   Retrospective comparative studies                             1
  Follow-up duration,*^c^* mo                                    25-151
  Defects (n = 589), n (%)                                       
   Primary                                                       498 (85)
   Secondary                                                     91 (15)
  Berndt and Harty classification (n = 156), n (%)               
   Stage I                                                       6 (4)
   Stage II                                                      26 (17)
   Stage III                                                     30 (19)
   Stage IV                                                      28 (18)
   Stage V                                                       66 (42)
  RTS rate (n = 300),*^c^* mean (95% CI), %                      22-100 (6-100)
  RTS rate to preinjury level (n = 300),*^c^* mean (95% CI), %   21-100 (8-100)
  Time to RTS (n = 133),*^c^* wk                                 13-26
  -------------------------------------------------------------- ----------------

*^a^*RTS, return to sports.

*^b^*References [@bibr1-2325967119876238], [@bibr13-2325967119876238], [@bibr17-2325967119876238], [@bibr21-2325967119876238], [@bibr22-2325967119876238], [@bibr27-2325967119876238], [@bibr28-2325967119876238], [@bibr31-2325967119876238], [@bibr32-2325967119876238], [@bibr36-2325967119876238], [@bibr39-2325967119876238], [@bibr46-2325967119876238], [@bibr48-2325967119876238], [@bibr61-2325967119876238], [@bibr63-2325967119876238] [@bibr64-2325967119876238]--[@bibr65-2325967119876238], [@bibr76-2325967119876238], [@bibr85-2325967119876238], [@bibr86-2325967119876238], [@bibr98-2325967119876238].

*^c^*Range of means of original data.

A simplified pooling method was used for 5 studies (all retrospective case series) reporting on RTS after treatment with autografts.^[@bibr21-2325967119876238],[@bibr22-2325967119876238],[@bibr46-2325967119876238],[@bibr61-2325967119876238],[@bibr63-2325967119876238]^ When pooled, it was calculated that 90% (95% CI, 86%-94%) of the 194 patients could return to sports regardless of the level ([Table 5](#table5-2325967119876238){ref-type="table"}). Four studies, with 67 patients, reported on the specific level of sports activity postoperatively^[@bibr21-2325967119876238],[@bibr22-2325967119876238],[@bibr46-2325967119876238],[@bibr61-2325967119876238]^; 72% (95% CI, 60%-83%) of these patients were able to participate in sports at their preinjury level, while 13% (95% CI, 8%-27%) had some limitations and 15% (95% CI, 6%-23%) were unable to return to sports ([Table 6](#table6-2325967119876238){ref-type="table"}).

The most commonly used outcome measure was the Tegner score, reported by 4 studies.^[@bibr39-2325967119876238],[@bibr63-2325967119876238],[@bibr65-2325967119876238],[@bibr85-2325967119876238]^ Mean follow-up times ranged from 13 to 151 months. Mean preoperative scores ranged from 1.9 to 5.9, and mean postoperative scores ranged from 3.5 to 5.8. No correlations were observed between the length of the follow-up period and the increase in the Tegner score. Other reported scores within this group were the FAOS sports score, reported by 1 study,^[@bibr13-2325967119876238]^ the FAAM sports subscale, reported by 1 study,^[@bibr1-2325967119876238]^ and the Valderrabano activity score, reported by 1 study.^[@bibr86-2325967119876238]^ Because of low reporting, these scores were not further analyzed.

### Cartilage Implantation {#section17-2325967119876238}

The aim of cartilage implantation techniques is to regenerate damaged tissue with hyaline-like type II cartilage. There were 8 studies identified with a total of 171 patients.^[@bibr3-2325967119876238],[@bibr4-2325967119876238],[@bibr9-2325967119876238],[@bibr12-2325967119876238],[@bibr23-2325967119876238],[@bibr24-2325967119876238],[@bibr51-2325967119876238],[@bibr55-2325967119876238]^ An overview of the study characteristics, patient characteristics, and outcomes within this group is shown in [Table 8](#table8-2325967119876238){ref-type="table"}.

###### 

Overview of Study Characteristics, Patient Characteristics, and Outcomes for Cartilage Implantation*^a^*

![](10.1177_2325967119876238-table8)

  ------------------------------------------------------------- -----------------
  No. of studies                                                8*^b^*
  No. of patients                                               171
  Study type, n                                                 
   Prospective case series                                      4
   Retrospective case series                                    4
  Follow-up duration,*^c^* mo                                   20-67
  Defects (n = 172), n (%)                                      
   Primary                                                      111 (65)
   Secondary                                                    61 (35)
  Berndt and Harty classification                               N/A
  RTS rate (n = 118),*^c^* mean (95% CI), %                     40-100 (15-100)
  RTS rate to preinjury level (n = 88),*^c^* mean (95% CI), %   6-100 (1-100)
  Time to RTS*^c^*                                              N/A
  ------------------------------------------------------------- -----------------

*^a^*N/A, not available; RTS, return to sports.

*^b^*References [@bibr3-2325967119876238], [@bibr4-2325967119876238], [@bibr9-2325967119876238], [@bibr12-2325967119876238], [@bibr23-2325967119876238], [@bibr24-2325967119876238], [@bibr51-2325967119876238], [@bibr55-2325967119876238].

*^c^*Range of means of original data.

We were able to perform simplified pooling on 3 studies (all prospective case series) reporting on RTS after treatment with autologous chondrocyte implantation.^[@bibr4-2325967119876238],[@bibr23-2325967119876238],[@bibr55-2325967119876238]^ It was calculated that 87% (95% CI, 73%-94%) of the patients were able to return to sports, regardless of levels, for a total of 39 patients ([Table 5](#table5-2325967119876238){ref-type="table"}). All of these studies specified the level of sports activity postoperatively; of the 39 patients, 69% (95% CI, 54%-81%) were able to participate in sports activity at their preinjury levels, while 18% (95% CI, 9%-33%) had some limitations and 13% (95% CI, 6%-27%) were unable to return to sports ([Table 6](#table6-2325967119876238){ref-type="table"}).

One study reported patient outcomes using the FAAM sports subscale.^[@bibr55-2325967119876238]^ Because of low reporting, this score was not further analyzed.

### Chondrogenesis-inducing Techniques {#section18-2325967119876238}

Chondrogenesis-inducing techniques can be applied for larger, cystic OCDs and aim to induce cartilage (re)generation by means of a single-step procedure. There were 9 studies with a total of 225 patients identified.^[‡‡](#fn5-2325967119876238){ref-type="fn"}^ An overview of the study characteristics, patient characteristics, and outcomes within this group is shown in [Table 9](#table9-2325967119876238){ref-type="table"}.

###### 

Overview of Study Characteristics, Patient Characteristics, and Outcomes for Chondrogenesis-Inducing Techniques*^a^*

![](10.1177_2325967119876238-table9)

  ------------------------------------------------------------- ---------------
  No. of studies                                                9*^b^*
  No. of patients                                               225
  Study type, n                                                 
   Retrospective case series                                    2
   Prospective case series                                      3
   Prospective cohort studies                                   2
   Prospective comparative studies                              1
   Retrospective comparative studies                            1
  Follow-up duration,*^c^* mo                                   8-60
  Defects (n = 146), n (%)                                      
   Primary                                                      114 (78)
   Secondary                                                    32 (22)
  Berndt and Harty classification (n = 50), n (%)               
   Stage III/IV*^d^*                                            50 (100)
  RTS rate (n = 79),*^c^* mean (95% CI), %                      64-92 (39-98)
  RTS rate to preinjury level (n = 49),*^c^* mean (95% CI), %   43-92 (16-98)
  Time to RTS*^c^*                                              N/A
  ------------------------------------------------------------- ---------------

*^a^*N/A, not available; RTS, return to sports.

*^b^*References [@bibr8-2325967119876238], [@bibr11-2325967119876238], [@bibr25-2325967119876238], [@bibr35-2325967119876238], [@bibr42-2325967119876238], [@bibr54-2325967119876238], [@bibr62-2325967119876238], [@bibr71-2325967119876238], [@bibr74-2325967119876238], [@bibr87-2325967119876238].

*^c^*Range of means of original data.

*^d^*Not further specified in studies.

A variety of outcome measures were reported within this group. The FAOS sports score was reported by 2 studies,^[@bibr35-2325967119876238],[@bibr54-2325967119876238]^ 1 study reported on the Foot and Ankle Disability Index (FADI) sports subscale,^[@bibr8-2325967119876238]^ and 1 study reported on the German Foot Function Index (FFI-D) sports subscale.^[@bibr25-2325967119876238]^ Because of low reporting, these scores were not further analyzed.

### Metal Implantation {#section19-2325967119876238}

This technique is used for medial talar OCDs after failed primary surgical treatment. After debriding of the defect, a metal resurfacing inlay implant (HemiCAP; Arthrosurface) is introduced into the defect, thereby resurfacing the extracted subchondral bone and the cartilage layer. There were 2 studies identified with a total of 49 patients.^[@bibr19-2325967119876238],[@bibr96-2325967119876238]^ An overview of the study characteristics, patient characteristics, and outcomes within this group is shown in [Table 10](#table10-2325967119876238){ref-type="table"}.

###### 

Overview of Study Characteristics, Patient Characteristics, and Outcomes for Metal Implantation*^a^*

![](10.1177_2325967119876238-table10)

  ------------------------------------------ -----------------
  No. of studies                             2*^b^*
  No. of patients                            49
  Study type, n                              
   Prospective case series                   1
   Retrospective case series                 1
  Follow-up duration,*^c^* mo                48-61
  Defects (n = 49), n (%)                    
   Secondary                                 49 (100)
  Berndt and Harty classification            N/A
  RTS rate (n = 32),*^c^* mean (95% CI), %   78-100 (59-100)
  RTS rate to preinjury level*^c^*           N/A
  Time to RTS (n = 32),*^c^* wk              16.5-17.5
  ------------------------------------------ -----------------

*^a^*N/A, not available; RTS, return to sports.

*^b^*References [@bibr19-2325967119876238], [@bibr96-2325967119876238].

*^c^*Range of means of original data.

One study reported outcomes using the FAOS sports score.^[@bibr96-2325967119876238]^ Because of low reporting, this score was not further analyzed.

Discussion {#section20-2325967119876238}
==========

To the best of our knowledge, this is the first systematic review investigating the RTS times and rates of all surgical treatment options for talar OCDs. The most important finding of the present study is that all of the surgical treatment options allowed for adequate RTS rates. However, RTS rates decreased substantially when RTS was defined as return to preinjury level. Additionally, performing simplified pooling for studies within the BMS, internal fixation, osteo(chondral) transplantation, and cartilage implantation groups yielded comparable pooled RTS rates. Furthermore, results on the mean RTS time were limited concerning quantity of reporting.

BMS was the most studied intervention; it is a commonly performed treatment worldwide, is relatively inexpensive in comparison with implantation techniques, and has low morbidity. For this treatment group, the pooled rate of RTS at any level of sport was 88%. This RTS rate is comparable to those of the pooled studies in the osteo(chondral) transplantation group describing the results of autograft (90% \[95% CI, 86%-94%\]) and those in the cartilage implantation group (87% \[95% CI, 73%-94%\]). When comparing the rates of return to preinjury level of sports between BMS (79% \[95% CI, 60%-83%\]), autograft (72% \[95% CI, 60%-83%\]), and cartilage implantation (69% \[95% CI, 54%-81%\]), there were no substantial differences observed either. The rate of return to preinjury level in the pooled BMS group was found to be in accordance with that in the systematic review of Ramponi et al,^[@bibr67-2325967119876238]^ who reported an RTS rate of 76.5% after treatment with BMS. It was however not clear whether these authors reported on return to preinjury level or return to any associated level of sports. A review by Hurley et al^[@bibr34-2325967119876238]^ showed that the rate of return to preinjury level of play for BMS was 87% for 248 patients. Although the authors provided levels of evidence for the included studies, studies with different methodological qualities were utilized to calculate this percentage, a methodological aspect that was not performed in the present study.

Return to preinjury level of sports presents the last step in the pathway of the RTS continuum, where return to participation is the first step,^[@bibr2-2325967119876238]^ followed by RTS at any associated level.^[@bibr2-2325967119876238]^ The rate of return to preinjury level of 79% after BMS can be considered as being relatively low when considering this continuum. However, it should be stated that is merely a short-term outcome after BMS, and the question therefore remains what the long-term sports activity level is of patients who have undergone BMS, as there are some factors that could play a vital role in the success of the long-term results. With BMS, the hyaline cartilage layer is not preserved, but the formation of a fibrin clot is promoted, after which fibrocartilaginous tissue or cartilage/collagen type I is formed. This tissue may decrease in quality over time, resulting in osteoarthritic changes.^[@bibr50-2325967119876238],[@bibr56-2325967119876238],[@bibr57-2325967119876238]^ This type of tissue demonstrates inferior wear characteristics compared with the original hyaline cartilage (cartilage/collagen type II), which can lead to degradation of the repaired surface. Research indicates that deterioration of the natural congruency of the ankle joint can occur as a result.^[@bibr52-2325967119876238],[@bibr66-2325967119876238],[@bibr84-2325967119876238]^ With this in mind, if possible, internal fixation could be a more appropriate treatment option for primary OCDs with a fixable radiological and intraoperative fragment.

Internal fixation aims to preserve the hyaline cartilage without causing additional clinical issues, such as donor site morbidity for the autograft group. Our pooled results for RTS at any level after internal fixation (97%) appear promising but were not substantially superior because of the lower number of patients within this treatment group. However, new data on this treatment option could be presented, as novel fixation techniques are being described, showing good short-term initial results.^[@bibr37-2325967119876238]^

Analysis of the methodological quality of the included studies showed that most were of low methodological quality, except for 4 randomized controlled trials.^[@bibr1-2325967119876238],[@bibr26-2325967119876238],[@bibr69-2325967119876238],[@bibr85-2325967119876238]^ This was demonstrated by the scores given for methodological quality according to the MINORS criteria ([Appendix Table A3](#table13-2325967119876238){ref-type="table"}). These findings are in accordance with those of prior systematic reviews^[@bibr10-2325967119876238],[@bibr45-2325967119876238],[@bibr95-2325967119876238],[@bibr97-2325967119876238]^ and underline the clear need for more high-quality randomized studies. Future research should be more focused on conducting randomized comparative clinical trials with extensive follow-up times and uniformity in methodology and outcome assessments. Treatment techniques from different treatment groups as well as within the same treatment group could be compared in this manner.

The present review has a number of limitations. The 2 most important limitations are the high number of methodologically low-quality studies that were included and the substantial heterogeneity in the methodology of the included studies. Heterogeneity was also observed in the used outcome measures. Some studies reported outcomes other than the RTS rate and the mean time to RTS, reporting scores from various outcome measures instead. Therefore, not all studies could be taken into account when calculating the RTS rate and the mean time to RTS, which left the results of return to preinjury level and mean time to RTS underreported and subsequently leaves a possibility for the results being subject to reporting bias.

In addition, it was not possible to perform a formal meta-analysis. Instead, a simplified pooling method was used for studies with the same methodology that reported outcomes after performing the same treatment technique. As the pooled studies were all of methodologically low quality, the evidence retrieved from this simplified pooling method was based on a lower level of evidence and may contain methodological bias. We deliberately did not choose a comparative character for the present study, as RTS rates and times were highly underreported when assessing sports outcomes, and more importantly, specific clinical indications for specific surgical therapies were highly different from one another. Therefore, it should be explicitly stated that the pooled calculated RTS rates should not be used for decision making with respect to treatment options but should merely be applied to give patients an indication on the expected RTS rates and times for the different available treatment options. The outcomes of the present study can therefore be utilized as a novel informative guideline on sports-specific prognosis for patients with primary and secondary talar OCDs aiming to return to (preinjury level of) sports.

The main strength of the present review is the extensive screening protocol, which resulted in a large number of included articles. A total of 536 articles were included for full-text reading to include all studies that reported any sports-related outcomes ([Figure 1](#fig1-2325967119876238){ref-type="fig"}). Other strengths are the inclusion of different treatment options, the inclusion of a large number of patients, and the quality assessment of the included studies. Another strength of the present study was the extensive author contact protocol regarding additional data retrieval and further clarification on the methodology of the included studies. Last, it should be stated that the results were pooled in a methodologically correct way to retrieve relevant, unbiased findings.

The clinical relevance of the present systematic review is that the separate and pooled RTS rates and the mean times to RTS for the different surgical treatment options can be used to give patients an indication of expected outcomes when undergoing treatment for talar OCDs. The results can contribute to clinical decision-making as well as the shared decision-making process between patients and physicians, which should be an individualized approach in which close and frequent communication between surgeon, athlete, and trainer or physical therapist occurs.^[@bibr14-2325967119876238]^

Conclusion {#section21-2325967119876238}
==========

The different surgical treatment options for talar OCD all allowed for adequate RTS times and rates. RTS rates decreased when considering patients' return to preinjury levels versus return at any level.
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Full Electronic Search Strategy Used in This Review
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#                 Search Terms                                                                                                                                                                                                                                                                                                                Total No. of Results
  ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------
  PubMed                                                                                                                                                                                                                                                                                                                                         

  1                  "Osteochondritis Dissecans"\[MeSH\]                                                                                                                                                                                                                                                                                         1139\

  2                  osteochondritis dissecans\[tiab\] OR osteochondrosis dissecans\[tiab\] OR osteochondrolysis\[tiab\] OR OCD\[tiab\] OR OLT\[tiab\]                                                                                                                                                                                           

  3                  (osteochondral\[tiab\] OR chondral\[tiab\] OR transchondral\[tiab\] OR cartilage\*\[tiab\]) AND (defect\*\[tiab\] OR lesion\*\[tiab\])                                                                                                                                                                                      

  4                  \#1 OR \#2 OR \#3                                                                                                                                                                                                                                                                                                           

  5                  "Talus"\[MeSH\]                                                                                                                                                                                                                                                                                                             

  6                  talus\[tiab\] OR talar\*\[tiab\] OR ankle\[tiab\]                                                                                                                                                                                                                                                                           

  7                  \#5 OR \#6                                                                                                                                                                                                                                                                                                                  

  8                  \#4 AND \#7                                                                                                                                                                                                                                                                                                                 

  Embase (Ovid)                                                                                                                                                                                                                                                                                                                                  

  1                  (osteochondritis dissecans/ or (osteochondritis dissecans or osteochondrosis dissecans or osteochondrolysis or OCD or OLT).ti, ab, kw. or ((osteochondral or chondral or osteochondral or transchondral or cartilage\*) adj3 (defect\* or lesion\*)).ti, ab, kw.) and (talus/ or (talus or talar\* or ankle).ti, ab, kw.)   1580

  2                  Limit 1 to yr="1996 -Current"                                                                                                                                                                                                                                                                                               1181

  Cochrane Library                                                                                                                                                                                                                                                                                                                               

  1                  MeSH descriptor: \[Osteochondritis Dissecans\] explode all trees                                                                                                                                                                                                                                                            8

  2                  osteochondritis dissecans or osteochondrosis dissecans or osteochondrolysis or OCD or OLT: ti, ab, kw (word variations have been searched)                                                                                                                                                                                  1302

  3                  (osteochondral or chondral or transchondral or cartilage\*) and (defect\* or lesion\*): ti, ab, kw (word variations have been searched)                                                                                                                                                                                     436

  4                  \#1 or \#2 or \#3                                                                                                                                                                                                                                                                                                           1716

  5                  MeSH descriptor: \[Talus\] explode all trees                                                                                                                                                                                                                                                                                36

  6                  talus or talar\* or ankle: ti, ab, kw (word variations have been searched)                                                                                                                                                                                                                                                  5877

  7                  \#5 or \#6                                                                                                                                                                                                                                                                                                                  5877

  8                  \#4 and \#7, publication year from 1996 to 2018, in Cochrane Reviews (Reviews and Protocols), Other Reviews and Trials                                                                                                                                                                                                      29
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

MINORS Criteria*^a^*

![](10.1177_2325967119876238-table12)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\. **A clearly stated aim:** The question addressed should be precise and relevant in light of the available literature.
  2\. **Inclusion of consecutive patients:** All patients potentially fit for inclusion (satisfying the criteria for inclusion) have been included in the study during the study period (no exclusion or details about the reasons for exclusion).
  3\. **Prospective collection of data:** Data were collected according to a protocol established before the beginning of the study.
  4\. **Endpoints appropriate to the aim of the study:** There is an unambiguous explanation of the criteria used to evaluate the main outcome, which should be in accordance with the question addressed by the study. Also, the endpoints should be assessed on an intention-to-treat basis.
  5\. **Unbiased assessment of the study endpoint:** A blind evaluation of objective endpoints and a double-blind evaluation of subjective endpoints should be conducted. Otherwise, the reasons for not blinding should be stated.
  6\. **Follow-up period appropriate to the aim of the study:** The follow-up should be sufficiently long to allow the assessment of the main endpoint and possible adverse events.
  7\. **Loss to follow-up less than 5%:** All patients should be included in the follow-up. Otherwise, the proportion lost to follow-up should not exceed the proportion experiencing the major endpoint.
  8\. **Prospective calculation of the study size:** There is information on the size of the detectable difference of interest with a calculation of the 95% CI, according to the expected incidence of the outcome event, and information about the level for statistical significance and estimates of power when comparing the outcomes.
  Additional criteria in the case of a comparative study
  9\. **An adequate control group:** There is a gold-standard diagnostic test or therapeutic intervention recognized as the optimal intervention according to the available published data.
  10\. **Contemporary groups:** Control and studied groups should be managed during the same time period (no historical comparison).
  11\. **Baseline equivalence of groups:** The groups should be similar regarding the criteria other than the studied endpoints. There should be an absence of confounding factors that could bias the interpretation of the results.
  12\. **Adequate statistical analyses:** Statistics are in accordance with the type of study with a calculation of confidence intervals or relative risks.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*^a^*The items are scored 0 (not reported), 1 (reported but inadequate), or 2 (reported and adequate). The global ideal score is 16 for noncomparative studies and 24 for comparative studies. MINORS, Methodological Index for Non-Randomized Studies.

###### 

MINORS Scores by Study*^a^*
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  First Author                                 Clearly Stated Aim   Inclusion of Consecutive Patients   Prospective Data Collection   Endpoints Appropriate to Aim of Study   Unbiased Assessment of Study Endpoint   Follow-up Period Appropriate to Aim of Study   \<5% Loss to Follow-up   Prospective Calculation of Sample Size   Adequate Control Group   Contemporary Groups   Baseline Equivalence of Groups   Adequate Statistical Analyses   Total
  -------------------------------------------- -------------------- ----------------------------------- ----------------------------- --------------------------------------- --------------------------------------- ---------------------------------------------- ------------------------ ---------------------------------------- ------------------------ --------------------- -------------------------------- ------------------------------- -------
  Ogut^[@bibr61-2325967119876238]^             2                    2                                   0                             2                                       0                                       1                                              0                        0                                                                                                                                                        7
  Dekker^[@bibr12-2325967119876238]^           2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Karnovsky^[@bibr35-2325967119876238]^        2                    2                                   0                             2                                       0                                       2                                              0                        0                                        2                        2                     2                                2                               16
  DeSandis^[@bibr13-2325967119876238]^         1                    2                                   0                             2                                       0                                       1                                              0                        0                                                                                                                                                        6
  Pagliazzi^[@bibr62-2325967119876238]^        1                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        7
  Sadlik^[@bibr74-2325967119876238]^           2                    2                                   2                             2                                       0                                       2                                              0                        0                                        2                        2                     2                                2                               18
  Vuurberg^[@bibr96-2325967119876238]^         2                    2                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        10
  Ogilvie-Harris^[@bibr58-2325967119876238]^   2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Bonnin^[@bibr6-2325967119876238]^            1                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        7
  Kumai^[@bibr43-2325967119876238]^            0                    0                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        4
  Ogilvie-Harris^[@bibr59-2325967119876238]^   0                    0                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        4
  Ogilvie-Harris^[@bibr60-2325967119876238]^   0                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        6
  Draper^[@bibr17-2325967119876238]^           2                    2                                   0                             2                                       0                                       2                                              0                        0                                        2                        2                     0                                2                               14
  Savva^[@bibr75-2325967119876238]^            2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Ferkel^[@bibr20-2325967119876238]^           2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Ventura^[@bibr94-2325967119876238]^          2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Dunlap^[@bibr18-2325967119876238]^           2                    0                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        6
  van Bergen^[@bibr88-2325967119876238]^       2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Kramer^[@bibr41-2325967119876238]^           2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Lee^[@bibr47-2325967119876238]^              2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Reilingh^[@bibr69-2325967119876238]^         2                    2                                   2                             2                                       2                                       2                                              0                        2                                        2                        2                     2                                2                               22
  van Eekeren^[@bibr92-2325967119876238]^      2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Kumai^[@bibr44-2325967119876238]^            0                    0                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        4
  Schuh^[@bibr77-2325967119876238]^            2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Kim^[@bibr38-2325967119876238]^              2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Sun^[@bibr85-2325967119876238]^              1                    2                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        9
  Guney^[@bibr26-2325967119876238]^            2                    2                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        10
  Hankemeier^[@bibr29-2325967119876238]^       0                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        6
  Murphy^[@bibr54-2325967119876238]^           2                    2                                   2                             2                                       0                                       2                                              2                        0                                                                                                                                                        12
  Saxena^[@bibr76-2325967119876238]^           2                    2                                   2                             2                                       0                                       2                                              2                        0                                                                                                                                                        12
  Domayer^[@bibr15-2325967119876238]^          2                    2                                   0                             2                                       0                                       1                                              0                        0                                                                                                                                                        7
  Rosenberger^[@bibr72-2325967119876238]^      0                    0                                   0                             2                                       0                                       1                                              0                        0                                                                                                                                                        3
  Lee^[@bibr46-2325967119876238]^              2                    1                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        7
  Haasper^[@bibr27-2325967119876238]^          2                    2                                   0                             2                                       0                                       1                                              0                        0                                                                                                                                                        7
  Valderrabano^[@bibr86-2325967119876238]^     2                    0                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        6
  Hangody^[@bibr28-2325967119876238]^          0                    2                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Kennedy^[@bibr36-2325967119876238]^          0                    0                                   0                             2                                       0                                       1                                              0                        0                                                                                                                                                        3
  Paul^[@bibr63-2325967119876238]^             2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Pearce^[@bibr64-2325967119876238]^           0                    2                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Hu^[@bibr32-2325967119876238]^               2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Leumann^[@bibr48-2325967119876238]^          2                    2                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        10
  Petersen^[@bibr65-2325967119876238]^         2                    2                                   2                             2                                       0                                       1                                              0                        0                                                                                                                                                        9
  Ahmad^[@bibr1-2325967119876238]^             2                    2                                   2                             2                                       0                                       2                                              0                        0                                        2                        2                     2                                2                               18
  Fraser^[@bibr21-2325967119876238]^           0                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        6
  Hintermann^[@bibr31-2325967119876238]^       2                    2                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        10
  Zhu^[@bibr98-2325967119876238]^              2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Kim^[@bibr39-2325967119876238]^              2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Gautier^[@bibr22-2325967119876238]^          0                    0                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        4
  Baums^[@bibr4-2325967119876238]^             0                    0                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        6
  Giannini^[@bibr23-2325967119876238]^         2                    2                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        10
  Giannini^[@bibr24-2325967119876238]^         2                    0                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        6
  Aurich^[@bibr3-2325967119876238]^            2                    2                                   2                             2                                       0                                       2                                              2                        0                                                                                                                                                        12
  Magnan^[@bibr51-2325967119876238]^           0                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        6
  Coetzee^[@bibr9-2325967119876238]^           2                    0                                   0                             2                                       0                                       1                                              0                        0                                                                                                                                                        5
  Nehrer^[@bibr55-2325967119876238]^           1                    2                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        9
  Valderrabano^[@bibr87-2325967119876238]^     2                    2                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        10
  Kubosch^[@bibr42-2325967119876238]^          2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8
  Gottschalk^[@bibr25-2325967119876238]^       2                    2                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        10
  Clanton^[@bibr8-2325967119876238]^           0                    2                                   2                             2                                       0                                       0                                              0                        0                                                                                                                                                        6
  Richter^[@bibr71-2325967119876238]^          2                    1                                   2                             2                                       0                                       2                                              0                        0                                                                                                                                                        9
  Ettinger^[@bibr19-2325967119876238]^         2                    2                                   0                             2                                       0                                       2                                              0                        0                                                                                                                                                        8

*^a^*MINORS, Methodological Index for Non-Randomized Studies.

###### 

Outcome Measures Reported by Treatment Strategy and Study*^a^*
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  First Author                                  Subcategory             Methodology   Sports Activity   Time to RTS   Tegner Score   FAOS Score   FAAM Score   FADI Score   Karlsson Score   FFI-D Score   Valderrabano Score   Martin Score   AAS Score
  --------------------------------------------- ----------------------- ------------- ----------------- ------------- -------------- ------------ ------------ ------------ ---------------- ------------- -------------------- -------------- -----------
  BMS                                                                                                                                                                                                                                          
   Ogilvie-Harris^[@bibr58-2325967119876238]^   BMS                     PCS                                                                                                                                                     x              
   Bonnin^[@bibr6-2325967119876238]^            BMS                     RCS                                           x                                                     x                                                                  
   Kumai^[@bibr43-2325967119876238]^            BMS                     RCS           x                                                                                                                                                        
   Ogilvie-Harris^[@bibr59-2325967119876238]^   BMS                     RCS           x                                                                                                                                         x              
   Ogilvie-Harris^[@bibr60-2325967119876238]^   BMS                     RCS           x                                                                                                                                         x              
   Draper^[@bibr17-2325967119876238]^           BMS                     R Comp        x                                                                                                                                                        
   Savva^[@bibr75-2325967119876238]^            BMS                     RCS           x                                                                                                                                                        
   Ferkel^[@bibr20-2325967119876238]^           BMS                     RCS           x                                                                                                                                                        
   Ventura^[@bibr94-2325967119876238]^          BMS                     RCS                             x             x                                                                                                                        
   Dunlap^[@bibr18-2325967119876238]^           BMS                     RCS           x                                                                                                                                                        
   van Bergen^[@bibr88-2325967119876238]^       BMS                     RCS           x                                                                                                                                                        
   Kramer^[@bibr41-2325967119876238]^           BMS                     RCS           x                 x                            x                                                                                                         
   Karnovsky^[@bibr35-2325967119876238]^        BMS                     R Comp                                                       x                                                                                                         
   Lee^[@bibr47-2325967119876238]^              BMS                     R Cohort                                                     x                                                                                                         
   Reilingh^[@bibr69-2325967119876238]^         BMS + PEMF              RCT           x                 x                                                                                                                                      x
   van Eekeren^[@bibr92-2325967119876238]^      BMS                     RCS           x                                              x                                                                                                         x
   Kim^[@bibr38-2325967119876238]^              BMS + PRP/MSC           R Comp                          x             x                                                                                                                        
   Sun^[@bibr85-2325967119876238]^              BMS                     RCT                                           x                                                                                                                        
   Guney^[@bibr26-2325967119876238]^            BMS + PRP/MSC           RCT                                                                       x                                                                                            
   Hankemeier^[@bibr29-2325967119876238]^       BMS                     RCS           x                                                                                                                                                        
   Murphy^[@bibr54-2325967119876238]^           BMS                     P Comp                                                       x                                                                                                         
   Saxena^[@bibr76-2325967119876238]^           BMS                     P Comp        x                 x                                                                                                                                      
   Domayer^[@bibr15-2325967119876238]^          BMS                     PCS           x                                                                                                                                                        
  Internal fixation                                                                                                                                                                                                                            
   Kumai^[@bibr44-2325967119876238]^            Drilling + fixation     RCS           x                                                                                                                                                        
   Schuh^[@bibr77-2325967119876238]^            Drilling + fixation     RCS           x                                                                                                                                                        
  Retrograde drilling                                                                                                                                                                                                                          
   Rosenberger^[@bibr72-2325967119876238]^      Retrograde drilling     RCS                                                          x                                                                                                         
  Osteo(chondral) transplantation                                                                                                                                                                                                              
   Saxena^[@bibr76-2325967119876238]^           Autograft               PCS           x                 x                                                                                                                                      
   Sun^[@bibr85-2325967119876238]^              Autograft               RCT                                           x                                                                                                                        
   Draper^[@bibr17-2325967119876238]^           Autograft               R Comp        x                                                                                                                                                        
   Lee^[@bibr46-2325967119876238]^              Autograft               RCS           x                                                                                                                                                        
   Haasper^[@bibr27-2325967119876238]^          Mosaicplasty            RCS           x                                                                                                                                                        
   Valderrabano^[@bibr86-2325967119876238]^     Mosaicplasty            RCS           x                                                                                                                    x                                   
   Hangody^[@bibr28-2325967119876238]^          Mosaicplasty            PCS           x                                                                                                                                                        
   Kennedy^[@bibr36-2325967119876238]^          Autograft               PCS           x                 x                                                                                                                                      
   Paul^[@bibr63-2325967119876238]^             Autograft               RCS           x                               x                                                                                                                        
   Pearce^[@bibr64-2325967119876238]^           Synthetic graft         PCS           x                                                                                                                                                        
   Hu^[@bibr32-2325967119876238]^               Osteoperiosteal graft   RCS           x                                                                                                                                                        
   Leumann^[@bibr48-2325967119876238]^          Mosaicplasty            PCS           x                                                                                                                                                        
   Petersen^[@bibr65-2325967119876238]^         Autograft               PCS           x                               x                                                                                                                        
   Ahmad^[@bibr1-2325967119876238]^             Autograft/allograft     RCT                                                                       x                                                                                            
   Fraser^[@bibr21-2325967119876238]^           Autograft               RCS           x                 x                                                                                                                                      
   Hintermann^[@bibr31-2325967119876238]^       Autograft               PCS           x                 x                                                                                                                                      
   Zhu^[@bibr98-2325967119876238]^              Autograft + allograft   RCS           x                                                                                                                                                        
   Kim^[@bibr39-2325967119876238]^              Autograft               RCS                                           x                                                                                                                        
   Gautier^[@bibr22-2325967119876238]^          Autograft               RCS           x                                                                                                                                                        
   Ogut^[@bibr61-2325967119876238]^             Autograft               RCS           x                                                                                                                                                        
   DeSandis^[@bibr13-2325967119876238]^         Synthetic graft         RCS                                                          x                                                                                                         
  Cartilage implantation                                                                                                                                                                                                                       
   Baums^[@bibr4-2325967119876238]^             ACI                     PCS           x                                                                                                                                                        
   Giannini^[@bibr23-2325967119876238]^         ACI                     PCS           x                                                                                                                                                        
   Giannini^[@bibr24-2325967119876238]^         ACI                     RCS           x                                                                                                                                                        
   Aurich^[@bibr3-2325967119876238]^            MACI                    PCS           x                                                                                                                                                        
   Magnan^[@bibr51-2325967119876238]^           ACI                     RCS           x                                                                                                                                                        
   Coetzee^[@bibr9-2325967119876238]^           ACI                     RCS           x                                                                                                                                                        
   Nehrer^[@bibr55-2325967119876238]^           MACI/ACI                PCS                                                                       x                                                                                            
   Dekker^[@bibr12-2325967119876238]^           PJCI                    RCS           x                                                                                                                                                        
  Metal implantation                                                                                                                                                                                                                           
   Ettinger^[@bibr19-2325967119876238]^         Metal implant           RCS           x                                                                                                                                                        
   Vuurberg^[@bibr96-2325967119876238]^         Metal implant           PCS                                                          x                                                                                                         
  Chondrogenesis-inducing techniques                                                                                                                                                                                                           
   Valderrabano^[@bibr87-2325967119876238]^     AMIC                    PCS           x                                                                                                                                                        
   Kubosch^[@bibr42-2325967119876238]^          AMIC                    PCS           x                                                                                                                                                        
   Gottschalk^[@bibr25-2325967119876238]^       AMIC                    P Cohort                                                                                                             x                                                 
   Clanton^[@bibr8-2325967119876238]^           Other                   RCS                                                                                    x                                                                               
   Pagliazzi^[@bibr62-2325967119876238]^        Other                   RCS           x                                                                                                                                                        
   Murphy^[@bibr54-2325967119876238]^           Other                   P Cohort                                                     x                                                                                                         
   Richter^[@bibr71-2325967119876238]^          Other                   PCS           x                                                                                                                                                        
   Karnovsky^[@bibr35-2325967119876238]^        Other                   RCS                                                          x                                                                                                         
   Sadlik^[@bibr74-2325967119876238]^           Other                   P Comp        x                                                                                                                                                        

*^a^*As there were several studies that reported outcomes for multiple treatment options (ie, comparative study), the total number of treatment strategies is higher than the total number of included studies. AAS, Ankle Activity Score; ACI, autologous chondrocyte implantation; AMIC, autologous matrix-induced chondrogenesis; BMS, bone marrow stimulation; FAAM, Foot and Ankle Ability Measure; FADI, Foot and Ankle Disability Index; FAOS, Foot and Ankle Outcome Score; FFI-D, German Foot Function Index; MACI, matrix-induced autologous chondrocyte implantation; MSC, mesenchymal stem cell; P Cohort, prospective cohort study; P Comp, prospective comparative study; PCS, prospective case series; PEMF, pulsed electromagnetic field; PJCI, particulated juvenile cartilage implantation; PRP, platelet-rich plasma; R Cohort, retrospective cohort study; R Comp, retrospective comparative study; RCS, retrospective case series; RCT, randomized controlled trial; RTS, return to sports.

[^1]: J.A.H.S. and J.D. both contributed equally to this work and thus share first authorship.
